Clinical trial
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
NCT00322257 · Novo Nordisk A/S, Industry · Terminated
Key facts
| NCT number | NCT00322257 |
|---|---|
| Title | Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes |
| Official title | Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 1 |
| Intervention type | Drug |
| Interventions | inhaled human insulin, insulin detemir, insulin aspart |
| Enrollment | 596 |
| Start date | May 1, 2006 |
| Primary completion | Apr 2, 2008 |
| Completion | Apr 2, 2008 |
| First posted | May 5, 2006 |
| Last update posted | Sep 5, 2018 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: